Research summary, original research, 2017

Evaluating Strategies For Reducing Scattered Radiation In Fixed-Imaging Hybrid Operating Suites

Miller C, Kendrick D, Shevitz A, Kim A, Baele H, Jordan D, et al.. Journal of vascular surgery. 2017

Read the original paper

In plain language

In 164 endovascular cases in a hybrid operating suite, adding dose reduction imaging software lowered patient dose-area product and the primary operator's measured dose, while real-time dose monitoring alone did not significantly change operator dose.

At a glance

Type of study
Original research, Prospective cohort study
Who was studied
Vascular surgeons, Mixed lab staff, Patients
Size
n = 164 endovascular cases
Summary based on
the abstract

What it found

  • Primary operator exposure did not change with real-time dose monitoring but fell significantly after dose reduction software was installed.

    Key figures: 0.08 ± 0.02 mSv vs 0.03 ± 0.01 mSv; P = .02

  • Mean dose-area product was significantly lower with dose reduction software than at baseline and than with real-time monitoring.

    Key figures: 186,173 ± 16,754 vs 121,536 ± 11,971 mGy/cm2; P = .002 (P1 vs P3); P = .04 (P2 vs P3)

  • The software had the greatest effect in endovascular aneurysm repair, reducing room dose and primary operator exposure.

    Key figures: 0.19 ± 0.04 mSv vs 0.03 ± 0.02 mSv; P < .01

  • Fluoroscopy time did not differ between phases, suggesting dose changes were not due to shorter procedures.

Limits to keep in mind

Single-centre sequential before-after phases with unequal, small group sizes and no randomization, so case mix and temporal changes may confound results; only abstract available.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.